2025

Gajic, N. et al. (2025) Selenocysteine Dependency Renders Central Nervous System Leukaemia Therapeutically Sensitive to Ferroptosi. 67th American Society of Hematology Annual Meeting, Orlando, USA, 06-09 Dec 2025. (doi: 10.1182/blood-2025-1526)

Gajic, N. et al. (2025) NADPH Controls a Cell State Vulnerability Towards Ferroptosis in Acute Lymphoblastic Leukaemia. 67th American Society of Hematology Annual Meeting, Orlando, USA, 06-09 Dec 2025. p. 144. (doi: 10.1182/blood-2025-144)

2024

Khalaf, A. et al. (2024) Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia. Science Translational Medicine, 16(751), eadi5336. (doi: 10.1126/scitranslmed.adi5336) (PMID:38865484)

Zarou, M. M. et al. (2024) Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1-mediated purine sensing. Nature Communications, 15, 1931. (doi: 10.1038/s41467-024-46114-0) (PMID:38431691) (PMCID:PMC10908830)

Dawson, A. et al. (2024) Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nature Communications, 15, 1090. (doi: 10.1038/s41467-024-45471-0) (PMID:38316788) (PMCID:PMC10844594)

Scott, M. T. et al. (2024) Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nature Communications, 15, 651. (doi: 10.1038/s41467-024-44771-9) (PMID:38246924) (PMCID:PMC10800356)

2023

Malik, Natasha ORCID: https://orcid.org/0000-0002-1768-3544, Hay, Jodie ORCID: https://orcid.org/0000-0002-2000-2578, Almuhanna, Hassan N.B., Dunn, Karen M., Lees, Jamie, Cassels, Jennifer, Li, Jiatian, Nakagawa, Rinako, Sansom, Owen J. ORCID: https://orcid.org/0000-0001-9540-3010 and Michie, Alison M. ORCID: https://orcid.org/0000-0002-5404-475X (2023) mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia, 37, pp. 2414-2425. (doi: 10.1038/s41375-023-02043-3) (PMID:37775560) (PMCID:PMC10681897)

Zarou, M. M. et al. (2023) Leukaemia Exposure Alters the Transcriptional Profile and Function of Macrophages in the Bone Marrow Niche. 65th ASH Annual Meeting and Exposition, San Diego, California, USA, 09-12 Dec 2023. (doi: 10.1182/blood-2023-181630)

Rattigan, K. M. et al. (2023) Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Reports, 24, e56279. (doi: 10.15252/embr.202256279) (PMID:37489735) (PMCID:PMC10561355)

Rattigan, K. M. et al. (2023) Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells. Nature Communications, 14, 4634. (doi: 10.1038/s41467-023-40222-z) (PMID:37591854) (PMCID:PMC10435520)

2022

Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)

2021

Ianniciello, A. et al. (2021) ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy. Science Translational Medicine, 13(613), eabd5016. (doi: 10.1126/scitranslmed.abd5016) (PMID:34586834)

2020

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

2019

Malik, Natasha ORCID: https://orcid.org/0000-0002-1768-3544, Dunn, Karen M., Cassels, Jennifer, Hay, Jodie ORCID: https://orcid.org/0000-0002-2000-2578, Estell, Christopher, Sansom, Owen J. ORCID: https://orcid.org/0000-0001-9540-3010 and Michie, Alison M. ORCID: https://orcid.org/0000-0002-5404-475X (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, 16917. (doi: 10.1038/s41598-019-53141-1) (PMID:31729420) (PMCID:PMC6858379)

Baquero, P. et al. (2019) Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 33(4), pp. 981-994. (doi: 10.1038/s41375-018-0252-4) (PMID:30185934) (PMCID:PMC6292500)

Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)

2017

Kuntz, Elodie M., Baquero, Pablo, Michie, Alison M. ORCID: https://orcid.org/0000-0002-5404-475X, Dunn, Karen, Tardito, Saverio ORCID: https://orcid.org/0000-0002-5294-8683, Holyoake, Tessa L., Helgason, G. Vignir ORCID: https://orcid.org/0000-0003-1616-132X and Gottlieb, Eyal ORCID: https://orcid.org/0000-0002-9770-0956 (2017) Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, 23(10), pp. 1234-1240. (doi: 10.1038/nm.4399) (PMID:28920959) (PMCID:PMC5657469)

2016

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi: 10.1158/2159-8290.CD-16-0263) (PMID:27630125) (PMCID:PMC6538532)

Sinclair, A. et al. (2016) CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 128(3), pp. 371-383. (doi: 10.1182/blood-2015-08-661785) (PMID:27222476) (PMCID:PMC4991087)

Abraham, S. A. et al. (2016) Dual targeting of P53 and C-MYC induces selective elimination of leukemic stem cells. Nature, 534(7607), pp. 341-346. (doi: 10.1038/nature18288) (PMID:27281222) (PMCID:PMC4913876)

2015

Nakagawa, R. et al. (2015) Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKC II expression in B lymphocytes. Haematologica, 100(4), pp. 499-510. (doi: 10.3324/haematol.2014.112276) (PMID:25616575) (PMCID:PMC4380723)

2013

Guitart, A.V. et al. (2013) Hif-2 is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood, 122(10), pp. 1741-1745. (doi: 10.1182/blood-2013-02-484923)

Articles

Khalaf, A. et al. (2024) Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia. Science Translational Medicine, 16(751), eadi5336. (doi: 10.1126/scitranslmed.adi5336) (PMID:38865484)

Zarou, M. M. et al. (2024) Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1-mediated purine sensing. Nature Communications, 15, 1931. (doi: 10.1038/s41467-024-46114-0) (PMID:38431691) (PMCID:PMC10908830)

Dawson, A. et al. (2024) Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nature Communications, 15, 1090. (doi: 10.1038/s41467-024-45471-0) (PMID:38316788) (PMCID:PMC10844594)

Scott, M. T. et al. (2024) Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nature Communications, 15, 651. (doi: 10.1038/s41467-024-44771-9) (PMID:38246924) (PMCID:PMC10800356)

Malik, Natasha ORCID: https://orcid.org/0000-0002-1768-3544, Hay, Jodie ORCID: https://orcid.org/0000-0002-2000-2578, Almuhanna, Hassan N.B., Dunn, Karen M., Lees, Jamie, Cassels, Jennifer, Li, Jiatian, Nakagawa, Rinako, Sansom, Owen J. ORCID: https://orcid.org/0000-0001-9540-3010 and Michie, Alison M. ORCID: https://orcid.org/0000-0002-5404-475X (2023) mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia, 37, pp. 2414-2425. (doi: 10.1038/s41375-023-02043-3) (PMID:37775560) (PMCID:PMC10681897)

Rattigan, K. M. et al. (2023) Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Reports, 24, e56279. (doi: 10.15252/embr.202256279) (PMID:37489735) (PMCID:PMC10561355)

Rattigan, K. M. et al. (2023) Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells. Nature Communications, 14, 4634. (doi: 10.1038/s41467-023-40222-z) (PMID:37591854) (PMCID:PMC10435520)

Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)

Ianniciello, A. et al. (2021) ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy. Science Translational Medicine, 13(613), eabd5016. (doi: 10.1126/scitranslmed.abd5016) (PMID:34586834)

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

Malik, Natasha ORCID: https://orcid.org/0000-0002-1768-3544, Dunn, Karen M., Cassels, Jennifer, Hay, Jodie ORCID: https://orcid.org/0000-0002-2000-2578, Estell, Christopher, Sansom, Owen J. ORCID: https://orcid.org/0000-0001-9540-3010 and Michie, Alison M. ORCID: https://orcid.org/0000-0002-5404-475X (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, 16917. (doi: 10.1038/s41598-019-53141-1) (PMID:31729420) (PMCID:PMC6858379)

Baquero, P. et al. (2019) Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 33(4), pp. 981-994. (doi: 10.1038/s41375-018-0252-4) (PMID:30185934) (PMCID:PMC6292500)

Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)

Kuntz, Elodie M., Baquero, Pablo, Michie, Alison M. ORCID: https://orcid.org/0000-0002-5404-475X, Dunn, Karen, Tardito, Saverio ORCID: https://orcid.org/0000-0002-5294-8683, Holyoake, Tessa L., Helgason, G. Vignir ORCID: https://orcid.org/0000-0003-1616-132X and Gottlieb, Eyal ORCID: https://orcid.org/0000-0002-9770-0956 (2017) Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, 23(10), pp. 1234-1240. (doi: 10.1038/nm.4399) (PMID:28920959) (PMCID:PMC5657469)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi: 10.1158/2159-8290.CD-16-0263) (PMID:27630125) (PMCID:PMC6538532)

Sinclair, A. et al. (2016) CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 128(3), pp. 371-383. (doi: 10.1182/blood-2015-08-661785) (PMID:27222476) (PMCID:PMC4991087)

Abraham, S. A. et al. (2016) Dual targeting of P53 and C-MYC induces selective elimination of leukemic stem cells. Nature, 534(7607), pp. 341-346. (doi: 10.1038/nature18288) (PMID:27281222) (PMCID:PMC4913876)

Nakagawa, R. et al. (2015) Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKC II expression in B lymphocytes. Haematologica, 100(4), pp. 499-510. (doi: 10.3324/haematol.2014.112276) (PMID:25616575) (PMCID:PMC4380723)

Guitart, A.V. et al. (2013) Hif-2 is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood, 122(10), pp. 1741-1745. (doi: 10.1182/blood-2013-02-484923)

Conference or Workshop Item

Gajic, N. et al. (2025) Selenocysteine Dependency Renders Central Nervous System Leukaemia Therapeutically Sensitive to Ferroptosi. 67th American Society of Hematology Annual Meeting, Orlando, USA, 06-09 Dec 2025. (doi: 10.1182/blood-2025-1526)

Gajic, N. et al. (2025) NADPH Controls a Cell State Vulnerability Towards Ferroptosis in Acute Lymphoblastic Leukaemia. 67th American Society of Hematology Annual Meeting, Orlando, USA, 06-09 Dec 2025. p. 144. (doi: 10.1182/blood-2025-144)

Zarou, M. M. et al. (2023) Leukaemia Exposure Alters the Transcriptional Profile and Function of Macrophages in the Bone Marrow Niche. 65th ASH Annual Meeting and Exposition, San Diego, California, USA, 09-12 Dec 2023. (doi: 10.1182/blood-2023-181630)